# **United States Live Biotherapeutic Products (LBPs) for Inflammatory Bowel Disease Market to Reach USD 0.81 Billion by 2034**

The **United States Live Biotherapeutic Products (LBPs) for Inflammatory Bowel Disease (IBD) Market** was valued at **USD 0.42 billion in 2026** and is projected to reach **USD 0.81 billion by 2034**, expanding at a **CAGR of 8.9%** during the forecast period. Market growth is fueled by the increasing prevalence of Crohn’s disease and ulcerative colitis, rising investment in microbiome-based therapies, and ongoing advancements in synthetic biology and precision medicine.

Live biotherapeutic products are biologically derived microorganisms developed to restore gut microbiome balance and improve intestinal health. Unlike conventional probiotics, LBPs undergo extensive clinical evaluation and are regulated as biologic therapies, making them a promising treatment option for inflammatory bowel disease.

Report Link: https://www.intelmarketresearc....h.com/united-states-